American Century Companies Inc. Has $37.35 Million Position in Repligen Co. (NASDAQ:RGEN)

American Century Companies Inc. cut its stake in shares of Repligen Co. (NASDAQ:RGEN) by 40.7% during the 2nd quarter, Holdings Channel reports. The fund owned 296,245 shares of the biotechnology company’s stock after selling 203,328 shares during the period. American Century Companies Inc.’s holdings in Repligen were worth $37,345,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Andra AP fonden bought a new stake in Repligen in the 2nd quarter valued at about $25,000. YHB Investment Advisors Inc. bought a new stake in shares of Repligen during the first quarter valued at approximately $26,000. International Assets Investment Management LLC acquired a new position in shares of Repligen during the second quarter worth approximately $33,000. Lazard Asset Management LLC lifted its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Principal Securities Inc. acquired a new stake in Repligen in the 4th quarter valued at $48,000. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Trading Down 2.6 %

Shares of Repligen stock opened at $136.39 on Wednesday. The firm has a market cap of $7.62 billion, a PE ratio of 545.56, a P/E/G ratio of 4.20 and a beta of 0.94. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a fifty day moving average price of $146.15 and a 200-day moving average price of $156.04.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RGEN. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.